1.The HTA secretariat and the European Medicines Agency shall exchange the information within the context of joint clinical assessment and joint scientific consultation as appropriate through the IT platform referred to in Article 30 of Regulation (EU) 2021/2282, consisting of a secure system for the exchange of information on the joint work, including the exchange of information with the European Medicines Agency (‘the HTA IT platform’).